AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

NEWS PROVIDED BY

AusperBio Therapeutics Inc.

Aug 27, 2026, 20:00 ET

SHARE THIS ARTICLE

Financing supports advancement of AHB-137 toward potential commercialization, including its Phase 3 registrational program and commercialization readiness

Proceeds will also accelerate AHB-171 and next-generation combination approaches designed to advance functional cure for chronic hepatitis B

Series C brings AusperBio's total capital raised to $360 million since 2024

SAN FRANCISCO, Aug. 27, 2026 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively "AusperBio" or the "Company"), a near-commercial biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other diseases, today announced the closing of its $120 million Series C financing.

The financing was led by a leading strategic investor, with participation from new investor RA Capital Management, L.P. ("RA Capital"), alongside continued support from AusperBio's existing investors, including HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. With the completion of the Series C, AusperBio has raised $360 million since 2024, reflecting strong and sustained investor confidence in the potential of the Company's lead programs and differentiated oligonucleotide platforms.

The financing will support the continued development of AHB-137, AusperBio's lead investigational ASO therapy for CHB, including its Phase 3 registrational program and commercialization readiness. Proceeds will also accelerate the development of AHB-171, the Company's investigational HBV siRNA candidate built on its proprietary Au-HALO™ targeted delivery platform, advance next-generation combination approaches for CHB, and further expand the Company's pipeline of targeted oligonucleotide therapeutics addressing significant unmet medical needs.

"This financing represents an important inflection point for AusperBio as we advance AHB-137 toward potential commercialization while developing next-generation therapies for CHB," said Dr. Guofeng Cheng, co-founder and CEO of AusperBio. "We are grateful for the continued confidence of our existing investors and pleased to welcome RA Capital to AusperBio. We look forward to building on this momentum to advance our strategy toward functional cure and unlock new opportunities across our oligonucleotide platforms."

Dr. Chris Yang, co-founder and CSO of AusperBio, added, "AHB-137 has demonstrated promising clinical activity in patients and has the potential to serve as a backbone therapy for functional cure of CHB. Our Med-Oligo™ ASO, Au-HALO™ targeted delivery and siRNA discovery platforms enable complementary approaches designed to achieve deeper and more durable antiviral responses. This financing will enable us to further advance these platforms and build on their potential to generate differentiated targeted oligonucleotide therapies for CHB and other diseases with significant unmet medical needs."

About AHB-137

AHB-137 is AusperBio's lead investigational unconjugated antisense oligonucleotide (ASO) therapy for chronic hepatitis B (CHB), developed using the Company's proprietary Med-Oligo™ ASO platform. AHB-137 is designed to suppress hepatitis B surface antigen (HBsAg) production, inhibit viral DNA replication, and promote immune reactivation, with the goal of achieving a functional cure for CHB. AHB-137 has demonstrated promising clinical results and is currently being evaluated in a Phase 3 trial in China, following completion of a global Phase 1 study and multiple Phase 2 studies. The Company is advancing AHB-137 through a coordinated global development strategy toward potential commercialization. AHB-137 is an investigational product candidate and has not been approved by any regulatory authority.

About AHB-171

AHB-171 is an investigational hepatocyte-targeted siRNA therapeutic candidate for the treatment of CHB that leverages AusperBio's proprietary Au-HALO™ liver-targeting delivery platform. AHB-171 is designed to selectively suppress viral gene expression and provide potent and sustained antiviral activity. As the first clinical candidate developed using the Au-HALO™ platform, AHB-171 is advancing the clinical validation of the Company's targeted delivery and siRNA capabilities and broadening the Company's differentiated HBV pipeline. AHB-171 is an investigational product candidate and has not been approved by any regulatory authority.

About Chronic Hepatitis B

Chronic hepatitis B remains a significant global health burden, affecting an estimated 254 million people worldwide and causing approximately 1.1 million deaths annually, primarily from cirrhosis and liver cancer, according to the World Health Organization. Current therapies can suppress viral replication but rarely achieve a functional cure, leaving many patients requiring long-term treatment.

About AusperBio

AusperBio is a near-commercial biopharmaceutical company focused on developing differentiated oligonucleotide therapeutics and targeted delivery technologies, with an initial focus on achieving a functional cure for chronic hepatitis B. The Company's innovation engine is built on its proprietary Med-Oligo™ ASO and Au-HALO™ targeted delivery platforms, supporting the development of therapies across multiple oligonucleotide modalities. With multiple clinical-stage programs and a growing pipeline, AusperBio is advancing a backbone-based combination strategy for functional cure of CHB while exploring opportunities in additional disease areas with significant unmet medical needs. For more information, visit www.ausperbio.com

Forward-Looking Statements

This press release is prepared by AusperBio (the "Company", "We") for informational purposes only. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as "anticipate", "expect", "intend", "plan", "believe", "continue", "could", "potential", "may", "will", "goal" or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words.

These forward-looking statements involve substantial known and unknown risks and uncertainties, including the risk that results in earlier clinical studies may not be indicative of future results and that any product candidates may not ultimately obtain required approvals or meaningfully improve patient outcomes, and other factors that are beyond the Company's control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.

Media Contact

Email: info@ausperbio.com

Investor Contact

Tel: 650-888-1756 (US)

Email: growth@ausperbio.com

SOURCE AusperBio Therapeutics Inc.

21%

more press release views with 

Request a Demo

Luxshare Precision Reports 40.2% Revenue Growth in First Half 2026; Business Mix Supports Margin Expansion USA - English

NEWS PROVIDED BY

Luxshare Precision Industry Co., Ltd.

Aug 27, 2026, 20:00 ET

SHARE THIS ARTICLE

Broad-based growth across consumer electronics, communications and data center, and automotive electronics, supported by targeted investment in AI infrastructure, intelligent vehicles and global delivery capacity

DONGGUAN, China, Aug. 28, 2026 /PRNewswire/ -- Luxshare Precision Industry Co., Ltd. ("Luxshare Precision" or the "Company") (SZSE: 002475; HKEX: 02475), a global provider of precision intelligent manufacturing solutions, today announced unaudited results for the six months ended June 30, 2026.

Revenue increased 40.2% year over year to RMB 174.50 billion, while net profit attributable to shareholders rose 18.0% to RMB 7.84 billion. Net profit attributable to shareholders excluding non-recurring gains and losses increased 6.5% to RMB 5.96 billion. Gross margin expanded by 17 basis points to 11.78%.

The margin improvement reflected operating leverage and a more diversified revenue mix, with faster growth in Communications and Data Center and Automotive Electronics, both of which carry gross margins above the Company average. Internal innovation, AI-enabled manufacturing efficiency and disciplined cost management also helped absorb pressure from foreign-exchange movements, higher input costs and investment in new businesses.

"Our first-half performance demonstrates the resilience of Luxshare Precision's diversified portfolio and global operating platform," said Wang Laichun, Chairwoman and General Manager of Luxshare Precision. "We are investing with discipline in areas supported by clear customer demand and defined technology roadmaps, particularly AI-enabled devices, AI infrastructure and intelligent vehicles. Our priorities remain execution, operating efficiency and sustainable value creation."

Strategic Investment and Financial Discipline

Research and development investment increased 43.1% to RMB 6.57 billion, primarily reflecting higher spending on engineering talent, tooling, materials and certification. More than half of the Company's R&D investment supported technology preparation for programs approaching commercialization.

Capital expenditures totaled RMB 10.27 billion, up RMB 742 million year over year, and were mainly directed toward overseas facility expansion, supporting infrastructure and new product lines. The Company prioritizes investments linked to customer programs, localized delivery and long-term manufacturing flexibility.

Inventory was RMB 50.37 billion at June 30, 2026, up 19.0% from year-end 2025, below the Company's 40.2% revenue growth. The increase primarily reflected business expansion and strategic material preparation for selected products.

First-half operating cash flow was an outflow of RMB 2.45 billion, mainly due to seasonal supplier payments and more than RMB 5 billion of strategic inventory preparation. Operating cash flow turned positive in the second quarter, reaching RMB 4.62 billion.

Foreign-exchange volatility resulted in approximately RMB 1.99 billion of losses on foreign-currency-denominated monetary assets and liabilities. Foreign-exchange risk management activities generated approximately RMB 1.30 billion in related gains. Under applicable accounting treatment, these gains were recorded as non-recurring items, while the corresponding losses remained within both disclosed net profit measures.

Growth Across Three Core Businesses

Consumer Electronics revenue increased 19.3% to RMB 122.48 billion. Luxshare Precision continued to deepen core customer relationships and strengthen its ODM and end-to-end product development capabilities. By integrating expertise across acoustics, optics, electrical systems, thermal management, magnetics and precision structures, the Company is extending its participation from components and modules to product definition, system development and volume manufacturing. Priority areas include AI PCs, smart wearables, AI glasses and intelligent acoustic products.

Communications and Data Center revenue increased 49.7% to RMB 16.61 billion. The Company is building an integrated AI infrastructure portfolio spanning high-speed copper interconnects, optical interconnects, thermal management and power management. Operational progress included volume production of 800G optical products, batch shipments of 1.6T DAC, ACC and AEC products, continued customer introductions for liquid-cooling solutions, and scaled production of DC-DC server power modules. Luxshare Precision is also advancing 224G and 448G copper technologies and next-generation optical architectures.

Automotive Electronics revenue increased 274.1% to RMB 32.39 billion, supported by organic growth, customer program ramps and Leoni's contribution. The Company continued to expand its portfolio across connectors, wiring harnesses, intelligent control systems, smart chassis technologies and powertrain solutions. High-speed connectors and rear-wheel steering products have entered mass production, while intelligent cockpit and advanced driver-assistance platforms are progressing across multiple vehicle programs. Leoni's integration continued to outperform expectations, strengthening global customer access, engineering resources and localized delivery capabilities.

Global Platform and Outlook

Luxshare Precision operates across five continents, 29 countries and more than 100 production sites. This network supports localized delivery, customer collaboration and supply chain resilience. The Company's vertically integrated platform spans precision components, functional modules and system-level products, supported by AI-enabled digital tools for quality management, predictive maintenance, production scheduling and standardized global execution.

For the remainder of 2026, Luxshare Precision will continue supporting consumer electronics product launches and ODM/JDM programs; accelerating commercialization across high-speed interconnects, optical products, liquid cooling and power management; and expanding automotive customer programs while capturing further benefits from the Leoni integration.

The Company will maintain disciplined capital allocation and continue investing in technology, manufacturing capacity and global delivery capabilities that support sustainable, high-quality growth.

About Luxshare Precision

Luxshare Precision Industry Co., Ltd. is a global provider of precision intelligent manufacturing solutions serving Consumer Electronics, Communications and Data Center, Automotive Electronics and other technology-driven industries. The Company supports customers from product definition and process development through new product introduction, volume manufacturing and global delivery.

21%

more press release views with 

Request a Demo

Luxshare Precision registra un crecimiento de ingresos del 40,2 % en el primer semestre de 2026 USA - español

NEWS PROVIDED BY

Luxshare Precision Industry Co., Ltd.

Aug 27, 2026, 20:00 ET

SHARE THIS ARTICLE

Luxshare Precision registra un crecimiento de ingresos del 40,2 % en el primer semestre de 2026; la diversificación de su negocio impulsa la expansión de los márgenes.

El crecimiento generalizado abarca electrónica de consumo, comunicaciones, centros de datos y electrónica de automoción, respaldado por inversiones estratégicas en infraestructura de IA, vehículos inteligentes y capacidad de distribución global

DONGGUAN, China  , 28 de agosto de 2026 /PRNewswire/ -- Luxshare Precision Industry Co., Ltd. ("Luxshare Precision" o "la compañía") (SZSE: 002475; HKEX: 02475), proveedor global de soluciones de fabricación inteligente de precisión, ha dado a conocer hoy los resultados no auditados para el semestre finalizado el 30 de junio de 2026.

Los ingresos aumentaron un 40,2 % en su cifra de año tras año hasta llegar a los 174.500 millones de RMB, mientras que el beneficio neto atribuible a los accionistas aumentó un 18,0 % hasta 7.840 millones de RMB. El beneficio neto atribuible a los accionistas, excluyendo ganancias y pérdidas no recurrentes, aumentó un 6,5 % hasta 5.960 millones de RMB. El margen bruto se expandió 17 puntos básicos hasta el 11,78 %.

La mejora del margen reflejó el apalancamiento operativo y una combinación de ingresos más diversificada, con un crecimiento más rápido en Comunicaciones y Centros de Datos y Electrónica de Automoción, los cuales tienen márgenes brutos superiores al promedio de la compañía. La innovación interna, la eficiencia de la fabricación basada en la IA y la gestión disciplinada de costes también ayudaron a absorber la presión de los movimientos de divisas, los mayores costes de los insumos y la inversión en nuevos negocios.

"Nuestro rendimiento en el primer semestre demuestra la resistencia de la cartera diversificada y la plataforma operativa global de Luxshare Precision", afirmó Wang Laichun, presidenta y directora general de Luxshare Precision. "Estamos invirtiendo con disciplina en áreas respaldadas por una clara demanda de los clientes y hojas de ruta tecnológicas definidas, en particular dispositivos habilitados para IA, infraestructura de IA y vehículos inteligentes. Nuestras prioridades siguen siendo la ejecución, la eficiencia operativa y la creación de valor sostenible".

Inversión estratégica y disciplina financiera

La inversión en investigación y desarrollo aumentó un 43,1 %, hasta alcanzar los 6.570 millones de RMB, debido principalmente al mayor gasto en talento de ingeniería, herramientas, materiales y certificación. Más de la mitad de la inversión en I+D de la compañía se destinó a la preparación tecnológica para programas próximos a su comercialización.

Los gastos de capital llegaron a los 10.270 millones de RMB, lo que equivale a un aumento de 742 millones de RMB con respecto al año anterior, y se dirigieron principalmente a la expansión de las instalaciones en el extranjero, la infraestructura de apoyo y las nuevas líneas de productos. La compañía prioriza las inversiones vinculadas a programas de clientes, la entrega localizada y la flexibilidad de fabricación a largo plazo.

El inventario ascendía a 50.370 millones de RMB al 30 de junio de 2026, un 19,0 % más que a finales de 2025, cifra inferior al crecimiento de los ingresos de la compañía, que fue del 40,2 %. Este aumento reflejó principalmente la expansión del negocio y la preparación estratégica de materiales para determinados productos.

El flujo de caja operativo del primer semestre registró una salida de 2.450 millones de RMB, debido principalmente a los pagos estacionales a proveedores y a más de 5.000 millones de RMB destinados a la preparación estratégica de inventario. El flujo de caja operativo se tornó positivo en el segundo trimestre, alcanzando los 4.620 millones de RMB.

La volatilidad del tipo de cambio generó pérdidas de aproximadamente 1.990 millones de RMB en activos y pasivos monetarios denominados en moneda extranjera. Las actividades de gestión del riesgo cambiario generaron ganancias relacionadas de aproximadamente 1.300 millones de RMB. Según el tratamiento contable aplicable, estas ganancias se registraron como partidas no recurrentes, mientras que las pérdidas correspondientes se mantuvieron dentro de ambas medidas de beneficio neto divulgadas.

Crecimiento en tres negocios principales

Los ingresos de Electrónica de Consumo aumentaron un 19,3 % hasta alcanzar los 122.480 millones de RMB. Luxshare Precision continuó profundizando sus relaciones con los clientes clave y fortaleciendo sus capacidades de ODM y desarrollo integral de productos. A través de la integración de conocimientos especializados en acústica, óptica, sistemas eléctricos, gestión térmica, magnetismo y estructuras de precisión, la empresa está ampliando su participación, desde componentes y módulos hasta la definición de productos, el desarrollo de sistemas y la fabricación en volumen. Entre sus áreas prioritarias se incluyen ordenadores con IA, dispositivos portátiles inteligentes, gafas con IA y productos acústicos inteligentes.

Los ingresos de Comunicaciones y Centros de Datos crecieron un 49,7 % hasta llegar a los 16.610 millones de RMB. La empresa está desarrollando una cartera integrada de infraestructura de IA que abarca interconexiones de cobre de alta velocidad, interconexiones ópticas, gestión térmica y gestión de energía. Entre los avances operativos se incluyen la producción en volumen de productos ópticos de 800G, envíos por lotes de productos DAC, ACC y AEC de 1,6T, la presentación continua a clientes de soluciones de refrigeración líquida y la producción a gran escala de módulos de alimentación para servidores CC-CC. Luxshare Precision también está impulsando las tecnologías de cobre de 224G y 448G, así como las arquitecturas ópticas de próxima generación.

Los ingresos de la división de Electrónica de Automoción aumentaron un 274,1 %, hasta alcanzar los 32.390 millones de RMB, gracias al crecimiento orgánico, la expansión de los programas de clientes y la contribución de Leoni. La compañía siguió ampliando su cartera de productos, que incluye conectores, arneses de cableado, sistemas de control inteligente, tecnologías de chasis inteligentes y soluciones para el tren motriz. Los conectores de alta velocidad y los productos para la dirección de las ruedas traseras han entrado en producción en masa, al tiempo que las plataformas de cabina inteligente y de asistencia al conductor avanzada progresan en diversos programas de vehículos. La integración de Leoni siguió superando las expectativas, fortaleciendo el acceso global a los clientes, los recursos de ingeniería y las capacidades de entrega localizadas.

Plataforma global y previsiones

Luxshare Precision opera en cinco continentes, 29 países y más de 100 centros de producción. Esta red permite la entrega localizada, la colaboración con el cliente y la resiliencia de la cadena de suministro. La plataforma integrada verticalmente de la compañía abarca componentes de precisión, módulos funcionales y productos a nivel de sistema, respaldados por herramientas digitales con IA para la gestión de la calidad, el mantenimiento predictivo, la planificación de la producción y la ejecución global estandarizada.

Durante el resto del año 2026, Luxshare Precision seguirá apoyando los lanzamientos de productos electrónicos de consumo y los programas ODM/JDM; acelerando la comercialización de interconexiones de alta velocidad, productos ópticos, refrigeración líquida y gestión de energía; y ampliando los programas para clientes del sector de la automoción, aprovechando al mismo tiempo los beneficios de la integración de Leoni.

La compañía mantendrá una asignación de capital disciplinada y continuará invirtiendo en tecnología, capacidad de fabricación y capacidades de entrega global que respalden un crecimiento sostenible y de alta calidad.

Acerca de Luxshare Precision

Luxshare Precision Industry Co., Ltd. es un proveedor global de soluciones de fabricación inteligente de precisión que presta servicios a los sectores de electrónica de consumo, comunicaciones y centros de datos, electrónica de automoción y otras industrias impulsadas por la tecnología. La empresa apoya a sus clientes desde la definición del producto y el desarrollo del proceso hasta la introducción de nuevos productos, la fabricación en volumen y la entrega global.

21%

more press release views with 

Request a Demo

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEWS PROVIDED BY

THE ROSEN LAW FIRM, P. A.

Aug 27, 2026, 20:11 ET

SHARE THIS ARTICLE

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.

So what: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the ARS Pharmaceuticals class action, go to https://rosenlegal.com/cases/ars-pharmaceuticals-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants provided investors with material information concerning ARS Pharmaceuticals' expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Defendants' statements included, among other things, confidence that this coverage would begin on July 1, 2026, and be in place for the summer and back-to-school allergy seasons.

According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark. This caused shareholders to purchase ARS Pharmaceuticals securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the ARS Pharmaceuticals class action, go to https://rosenlegal.com/cases/ars-pharmaceuticals-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     case@rosenlegal.com

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

21%

more press release views with 

Request a Demo

Midwest Fiber Networks and Midwest Fiberpath Announce Agreement to Advance 1,200-Mile Midwest Fiber Corridor

NEWS PROVIDED BY

Midwest FiberPath

Aug 27, 2026, 20:22 ET

SHARE THIS ARTICLE

Planned 1,200-mile route system will support long-haul connectivity, route diversity and high-capacity infrastructure across key Midwest markets

GLENDALE, Wis. and CEDAR RAPIDS, Iowa, Aug. 27, 2026 /PRNewswire/ -- Midwest Fiber Networks (MWFN) and Midwest Fiberpath, LLC (Fiberpath), with its partner Hawkeye Land Co. (Hawkeye) today announced an agreement supporting the development and commercialization of approximately 1,200 miles of strategic fiber corridors connecting major Midwest markets, including Chicago, Omaha, Minneapolis and Kansas City.

Through this agreement, MWFN will serve as the key provider supporting the commercialization and delivery of connectivity services across Hawkeye's right-of-way corridor. Planned service opportunities include conduit, dark fiber, and highly scalable lit services for carriers, hyperscalers, data centers, enterprises, utilities, private-sector organizations and public-sector organizations.

The corridor is designed to create a long-term regional infrastructure platform that provides customers with additional options for network capacity, geographic reach and route diversity across the Midwest.

"This agreement represents an important step in our continued growth across the Midwest," said Nik Ivancevic, Managing Partner of MWFN. "By working with Fiberpath and Hawkeye in Hawkeye's corridor, MWFN will be able to expand the connectivity options available to carriers, businesses and other network customers seeking scalable capacity and greater route diversity across key Midwest markets." 

"Midwest Fiberpath was created to develop scalable long-haul infrastructure across strategic corridors throughout middle America," said Ken Anderson, Managing Director of Fiberpath. "Our relationship with MWFN brings together regional market knowledge, operational experience and infrastructure expertise to help bring these routes to customers seeking flexible, high-capacity connectivity solutions."

Rick Stickle, CEO of Hawkeye and Managing Director of Fiberpath noted, "With this partnership, we believe we have found the highest and best of Hawkeye Land Co.'s property rights."

Construction is anticipated to begin in Spring 2027.

The project is already in advanced stages of engineering and materials procurement with scheduled shipments due before end of year 2026.

All three companies are aligned to establish the corridor as the foundation for long-term network expansion while helping address growing demand for resilient, high-capacity connectivity.

About Midwest Fiber Networks, LLC

Midwest Fiber Networks (MWFN) designs and delivers secure, high-speed fiber connectivity across the Midwest with a focus on reliability, redundancy, and customer satisfaction. With deep roots in telecommunications infrastructure and decades of experience, MWFN supports mission-critical operations for businesses, educational institutions, healthcare systems, and government entities. Through strategic partnerships and a rapidly growing footprint, MWFN is building the future of fiber—one mile at a time. For more information about Midwest Fiber Networks, visit midwestfibernetworks.com and follow MWFN on LinkedIn.

About Midwest FiberPath, LLC

Midwest FiberPath, LLC is a digital infrastructure company focused on developing scalable long-haul fiber corridor platforms across high-growth Midwest markets. The company is building a managed right-of-way system designed to support blank conduit, dense fiber deployments, route diversity, and long-term network expansion.

About Hawkeye Land Co.

Since 1985, Hawkeye Land Co., based in Cedar Rapids, Iowa, is the owner of the exclusive, perpetual right to grant easements along all former Rock Island Railroad corridors located in 106 Midwest counties in 4 key States. Those interests include the easement granting rights along the current rail corridors from Council Bluffs to Joliet and from Minneapolis to Kansas City. Hawkeye Land has managed these holdings, selling both crossing and longitudinal easements to utilities, municipalities and other applicants for over 40 years.

SOURCE Midwest FiberPath

21%

more press release views with 

Request a Demo

WSE Investors Have Opportunity to Lead Wise Group plc Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEWS PROVIDED BY

THE ROSEN LAW FIRM, P. A.

Aug 27, 2026, 20:47 ET

SHARE THIS ARTICLE

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Wise Group plc (NASDAQ: WSE) between May 11, 2026 and July 23, 2026, both dates inclusive (the "Class Period"), of the important September 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

So what: If you purchased Wise Group plc securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Wise Group plc class action, go to https://rosenlegal.com/cases/wise-group-plc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 29, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) in order to have a successful debut on the NASDAQ, defendants materially understated Wise's regulatory risks as a result of its materially deficient anti-money laundering efforts, as well as insufficient efforts to prevent the financing of terrorism; and (2) as a result, defendants' statements about Wise's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.  

To join the Wise Group plc class action, go to https://rosenlegal.com/cases/wise-group-plc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY  10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     case@rosenlegal.com 

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

21%

more press release views with 

Request a Demo